Bevacizumab is a vascular endothelial growth factor-A-specific angiogenesis inhibitor indicated as an adjunct to chemotherapy for the treatment of several types of cancer. Hypertension is commonly observed during bevacizumab treatment, and high-grade toxicity can limit therapy and lead to other cardiovascular complications. The factors that contribute to interindividual variability in blood pressure response to bevacizumab treatment are not well understood. In this review, we outline research efforts to understand the mechanisms and pathophysiology of hypertension resulting from bevacizumab treatment. Moreover, we highlight current knowledge of the pharmacogenetics of bevacizumab-induced hypertension, which may be used to develop strategies to prevent or minimize this toxicity.

贝伐单抗是一种血管内皮生长因子-A特异性血管生成抑制剂，被指示为化学疗法的辅助药物，可用于治疗多种类型的癌症。在贝伐单抗治疗期间通常会观察到高血压，高毒性会限制治疗并导致其他心血管并发症。人们对贝伐单抗治疗的血压反应中个体间差异的影响因素尚不清楚。在这篇综述中，我们概述了研究工作，以了解贝伐单抗治疗导致的高血压的机制和病理生理。此外，我们重点介绍了贝伐单抗诱发的高血压的药物遗传学知识，可用于开发预防或最小化这种毒性的策略。